C4 Therapeutics, Inc. (CCCC) stock forecast and price target
Price $2.76 · data as of November 13, 2026
12-month price target
Average target$12.50
Upside / downside+352.9%
Analysts8
ConsensusStrong buy
Low $6.00Average $12.50High $30.00
Gold marker: average target · white marker: today’s price ($2.76)
Analyst ratings
Strong buy 2Buy 7Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.74 | +34.9% | $27M |
| Next fiscal year ends December 31, 2027 | $-0.87 | −17.1% | $24M |
| Next quarter ends December 31, 2026 | $-0.20 | −10.0% | $6M |
| Quarter after ends March 31, 2027 | $-0.26 | −30.0% | $5M |
Consensus of the analysts covering C4 Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the C4 Therapeutics stock price target?
The average 12-month target from 8 analysts is $12.50, 352.9% above the current price of $2.76 Targets range from $6.00 to $30.00.
Is C4 Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 7 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is C4 Therapeutics expected to earn?
Analysts expect EPS of $-0.74 for the fiscal year ending December 31, 2026 and $-0.87 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.